[Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
D000284:Administration, Oral; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003653:Decarboxylation; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000627:therapeutic use; D004338:Drug Combinations; D004358:Drug Therapy / Q000266:history; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000266:history
D004338:Drug Combinations; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D004296:Dopa Decarboxylase
Vorteile der Kombinationsbehandlung (L-Dopa- und Dekarboxylasehemmer) des Parkinsonsyndroms.